225 related articles for article (PubMed ID: 17349625)
21. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.
Dumonteil E; Andrade-Narvarez F; Escobedo-Ortegon J; Ramirez-Sierra MJ; Valencia-Pacheco G; Flores-Serrano A; Canto-Lara S; Arjona-Torres A
Dev Biol (Basel); 2000; 104():135-41. PubMed ID: 11713811
[TBL] [Abstract][Full Text] [Related]
22. Leishmania amazonensis: cultivation and characterization of axenic amastigote-like organisms.
Hodgkinson VH; Soong L; Duboise SM; McMahon-Pratt D
Exp Parasitol; 1996 Jun; 83(1):94-105. PubMed ID: 8654556
[TBL] [Abstract][Full Text] [Related]
23. In vitro maintenance of Leishmania amastigotes directly from lesions: advantages and limitations.
Hodgkinson VH; Soong L
J Parasitol; 1997 Oct; 83(5):953-6. PubMed ID: 9379307
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
Parody N; Soto M; Requena JM; Alonso C
Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
[TBL] [Abstract][Full Text] [Related]
25. Leishmania mexicana H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice.
Daneshvar H; Hagan P; Phillips RS
Parasite Immunol; 2003; 25(11-12):589-96. PubMed ID: 15053780
[TBL] [Abstract][Full Text] [Related]
26. Mast cells are activated by Leishmania mexicana LPG and regulate the disease outcome depending on the genetic background of the host.
Villaseñor-Cardoso MI; Salaiza N; Delgado J; Gutiérrez-Kobeh L; Pérez-Torres A; Becker I
Parasite Immunol; 2008 Aug; 30(8):425-34. PubMed ID: 18507782
[TBL] [Abstract][Full Text] [Related]
27. Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice.
Barral-Netto M; de Freitas LA; Andrade ZA
Am J Pathol; 1987 May; 127(2):271-8. PubMed ID: 3495185
[TBL] [Abstract][Full Text] [Related]
28. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
29. Infection of BALB/c, C57B1/6 mice and F1 hybrid CB6F1 mice with strains of Leishmania mexicana isolated from Mexican patients with localized or diffuse cutaneous leishmaniasis.
Monroy-Ostria A; Fuentes-Fraga I; García-Flores C; Favila-Castillo L
Arch Med Res; 1994; 25(4):401-6. PubMed ID: 7858398
[TBL] [Abstract][Full Text] [Related]
30. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
31. Protection of C3HeB/FeJ mice against Leishmania amazonensis challenge after previous Leishmania major infection.
Vanloubbeeck Y; Jones DE
Am J Trop Med Hyg; 2004 Oct; 71(4):407-11. PubMed ID: 15516635
[TBL] [Abstract][Full Text] [Related]
32. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein.
Campbell K; Popov V; Soong L
Infect Immun; 2004 Apr; 72(4):2194-202. PubMed ID: 15039343
[TBL] [Abstract][Full Text] [Related]
33. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection.
Pereira WK; Lonardoni MV; Grespan R; Caparroz-Assef SM; Cuman RK; Bersani-Amado CA
J Infect; 2005 Aug; 51(2):157-64. PubMed ID: 16038768
[TBL] [Abstract][Full Text] [Related]
35. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
[TBL] [Abstract][Full Text] [Related]
36. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan.
Pinheiro RO; Pinto EF; de Matos Guedes HL; Filho OA; de Mattos KA; Saraiva EM; de Mendonça SC; Rossi-Bergmann B
Vaccine; 2007 Mar; 25(14):2716-22. PubMed ID: 16814903
[TBL] [Abstract][Full Text] [Related]
37. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection.
Alexander J; Brombacher F; McGachy HA; McKenzie AN; Walker W; Carter KC
Eur J Immunol; 2002 Oct; 32(10):2923-33. PubMed ID: 12355446
[TBL] [Abstract][Full Text] [Related]
38. [Production of monoclonal antibodies against Leishmania mexicana mexicana antigens].
Correnti M; Ortega G
Acta Cient Venez; 1991; 42(4):226-8. PubMed ID: 1843566
[TBL] [Abstract][Full Text] [Related]
39. Chronic antigen ingestion protects ovalbumin sensitized mice from severe manifestation of Leishmania major infection.
Saldanha JC; Gargiulo DL; Dourado LP; Santiago HC; Menezes GB; Reis ML; Tafuri WL; Teixeira MM; Vieira LQ; Cara DC
Parasite Immunol; 2008; 30(11-12):646-9. PubMed ID: 19067847
[TBL] [Abstract][Full Text] [Related]
40. Immune response and protection in mice inoculated with Leishmania amazonensis clones expressing different degrees of virulence.
da Fonseca AL; Vallochi AL; Furtado Gde C; Abrahamsohn Ide A; Lima GM
Parasitol Res; 1997; 83(7):690-7. PubMed ID: 9272560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
